Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Multiparameter System Featuring Wearable Biosensor Enables Near Real-Time Patient Monitoring

By HospiMedica International staff writers
Posted on 03 Dec 2024

A novel cloud-based system featuring a wearable biosensor with chest-based SpO2 monitoring enables continuous patient monitoring across both hospital and out-of-hospital care settings. More...

The UbiqVue 2A Multiparameter System, developed by LifeSignals (Milpitas, CA, USA), represents a significant advancement in wireless, continuous patient monitoring for population health management. This system can be used in home, remote, and hospital environments to monitor patients’ physiological data in real time, improving patient safety and replacing traditional spot-check methods that can be labor-intensive and prone to inaccuracies. At the core of this system is the UbiqVue 2A Biosensor, a single-use, all-in-one wearable device designed to continuously collect SpO2 data from the chest. It also tracks a total of 12 other vital parameters, including 2-channel ECG, pulse rate, PPG, respiration rate, body temperature, and motion.

The data collected by the biosensor is encrypted and transmitted securely in near real-time via a relay app or access point to a secure cloud system, where it undergoes signal processing. Healthcare professionals and caregivers can access this continuous stream of vital signs from anywhere through the UbiqVue web portal and receive alert notifications. Designed to integrate seamlessly into clinical workflows, UbiqVue offers scalability across healthcare systems. Following its FDA Class II 510(k) clearance, the UbiqVue 2A Multiparameter System is set to revolutionize both individualized patient care and broader population health strategies.

"This FDA 510(k) approval marks a major milestone in LifeSignals' mission to deliver bedside patient monitor-like functionality through an affordable, single-use disposable Biosensor, enabling population health management," said Surendar Magar, Co-founder and CEO. "It shows our commitment to the vision of expanding the UbiqVue system with additional vital signs and advanced AI capabilities. Through global partnerships with OEMs, service providers, IDTFs, and distributors, we aim to transform healthcare at scale."

Related Links:
LifeSignals


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.